 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 1st Annual H.C. Wainwright Hereditary Angioedema Conference virtual on Wednesday, July 20, 2022 at 12:00 p.m. ET. KalVista CEO Andrew Crockett will also participate as part of an expert panel discussing 